secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-05-06T23:59:59+00:00
Accession:  0001683168-22-003281
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health reports positive initial Phase I results for concussion drug PRV-002
--------------------------------------------------------------------------------

- First group of 5 healthy subjects dosed with PRV-002 showed safety and tolerability; no serious adverse events.
- Phase I trial ongoing with 48 healthy subjects in single and multi-ascending dose components.
- Company plans to present Phase I data to FDA, then initiate Phase II trial in US starting with military.
- Concussion affects over 3 million annually in US; no FDA-approved treatment currently exists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822003281/0001683168-22-003281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822003281/ody_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-003281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer